雌激素受体
医学
乳腺癌
雌激素
癌症
靶向治疗
选择性雌激素受体调节剂
内分泌系统
内科学
肿瘤科
生物信息学
生物
激素
作者
Senthil Damodaran,Gabriel N. Hortobágyi
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2021-11-01
卷期号:81 (21): 5396-5398
被引量:11
标识
DOI:10.1158/0008-5472.can-21-3200
摘要
Abstract Nearly two-thirds of breast cancers overexpress estrogen receptors, and endocrine therapy is considered the backbone of systemic therapy both in early and advanced settings. While this is now widely recognized in clinical practice, this is the culmination of outstanding contribution of many investigators and patients. Indubitably, estrogen receptor targeting has had the most impact among targeted therapies and has significantly affected patient survival. In this commentary, we revisit a landmark article published in Cancer Research in 1977 by Knight and colleagues, which laid the groundwork for the use of estrogen receptors in prognostication and adjuvant treatment selection, as well as some of the key breakthroughs in estrogen receptor biology that span more than a century. See related article by Knight and colleagues, Cancer Res 1977;37:4669–71
科研通智能强力驱动
Strongly Powered by AbleSci AI